Controlled degradation of stents

• US 8,267,990 B2
• Filed: 08/31/2010
• Issued: 09/18/2012
• Est. Priority Date: 07/17/2006
• Status: Active Grant

• Current Assignee: Advanced Cardiovascular Systems Incorporated
• Original Assignee: Advanced Cardiovascular Systems Incorporated
• Inventors: Gale, David C., Huang, Bin, Gueriguian, Vincent, Hossainy, Syed Faiyaz Ahmed
• Primary Examiner(s): Sweet, Thomas J
• Assistant Examiner(s): Stewart, Jason-Dennis
• Application Number:
  US12/872,166
• Publication Number:
  US 20110098803A1
• Time in Patent Office: 749 Days
• Field of Search: 427/2.24, 623/1.15, 623 138- 146
• US Class Current: 623/1.38
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Stents fabricated from hydrolytically degradable polymers with accelerated degradation rates and methods of fabricating stents with accelerated degradation rates are disclosed.

Claims

1. A method of treating a bodily lumen comprising:

releasing an acidic agent at or adjacent to a hydrolytically degradable polymer stent implanted within a bodily lumen, the acidic agent lowers the pH of bodily fluid at or adjacent to the stent, the lowered pH of the bodily fluid increases the degradation rate of the stent.

2. The method of claim 1, wherein the degradable polymer has a higher degradation rate at an acidic pH as compared to a physiological pH of bodily fluid.

3. The method of claim 1, wherein the pH of the bodily fluid is lowered from a physiological pH to less than 6.

4. The method of claim 1, wherein the acidic agent is released when drug delivery to the bodily lumen is completed and/or vascular support is no longer needed.

5. The method of claim 1, wherein the acidic agent is selected from the group consisting of biodegradable polymer having acidic end groups, a hydrophilic polymer having acidic end groups, and an acid.

6. The method of claim 1, wherein the acidic agent is selected from the group consisting of poly(ethylene glycol) with acid groups, poly(vinyl alcohol) with acid groups, poly(L-lactide) with a molecular weight less than about 5000, citric acid, acetic acid, and a combination thereof.

7. The method of claim 1, wherein the hydrolytically degradable polymer comprises PLLA.

8. A method of treating a bodily lumen comprising:

positioning a delivery device within a bodily lumen at or adjacent to a hydrolytically degradable polymer stent implanted within the bodily lumen;

disposing an acidic agent into the delivery device;

releasing the acidic agent from the delivery device into the bodily lumen, wherein the released acidic agent lowers the pH of the bodily fluid at or adjacent to the stent below physiological pH which increases the degradation rate of the stent.

9. The method of claim 8, wherein device comprises a porous inflatable member, the acidic agent being released through the pores of the inflatable member.

10. The method of claim 8, wherein device comprises an inflatable member, the inflatable member comprising needles protruding from an outer surface of the inflatable member into walls of the bodily lumen, the acidic agent being released through the needles of the inflatable member.

11. The method of claim 8, wherein disposing the acidic agent into device comprises injecting the acidic agent into a proximal end of a catheter, wherein the device is positioned on the distal end of the catheter, the device being in fluid communication with the catheter.

12. The method of claim 8, wherein the acidic agent is selected from the group consisting of biodegradable polymer having acidic end groups, a hydrophilic polymer having acidic end groups, and an acid.

13. The method of claim 8, wherein the acidic agent is selected from the group consisting of poly(ethylene glycol) with acid groups, poly(vinyl alcohol) with acid groups, poly(L-lactide) with a molecular weight less than about 5000, citric acid, acetic acid, and a combination thereof.

14. The method of claim 8, wherein the hydrolytically degradable polymer comprises poly(L-lactide).

15. The method of claim 8, wherein the device comprises a needle infusion catheter.

16. The method of claim 8, wherein the device comprises a porous balloon.